Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2022
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMSDouglas L Arnold, Till Sprenger, Amit Bar-Or, et al.
The Lancet. Neurology|November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-studyXavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.
Multiple Sclerosis and Related Disorders|September 10, 2020
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension studyAaron E Miller, Tomas P Olsson, Jerry S Wolinsky, et al.
Neurology|February 12, 2016
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO studyPaul O'Connor, Giancarlo Comi, Mark S Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2013
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialPatrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Pageof 14